Tuesday, September 07, 2021 8:15:21 AM
TRACON Pharmaceuticals, Inc.
Tue, September 7, 2021, 8:05 AM
SAN DIEGO, Sept. 07, 2021 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 23rd Annual Global Investment Conference, being held September 13-15, 2021.
The presentation will be available on-demand beginning at 7:00 AM Eastern Time on Monday, September 13, 2021, in the Investors section on the Company’s website at www.traconpharma.com.
About TRACON
TRACON develops targeted therapies for cancer utilizing a capital efficient, CRO independent, product development platform. The Company’s clinical-stage pipeline includes: Envafolimab, a PD-L1 single-domain antibody given by rapid subcutaneous injection that is being studied in the pivotal ENVASARC trial for sarcoma; TRC102, a Phase 2 small molecule drug candidate for the treatment of lung cancer; and TJ004309, a CD73 antibody in Phase 1 development for the treatment of advanced solid tumors. TRACON is actively seeking additional corporate partnerships whereby it leads U.S. regulatory and clinical development and shares in the cost and risk of clinical development and leads U.S. commercialization. In these partnerships TRACON believes it can serve as a solution for companies without clinical and commercial capabilities in the U.S. To learn more about TRACON and its product pipeline, visit TRACON's website at www.traconpharma.com.
Company Contact:
Investor Contact:
Mark Wiggins
Brian Ritchie
Chief Business Officer
LifeSci Advisors LLC
(858) 251-3492
(212) 915-2578
mwiggins@traconpharma.com
britchie@lifesciadvisors.com
Recent TCON News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/14/2024 09:00:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/14/2024 08:05:17 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/13/2024 09:00:43 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 12:00:12 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 03/07/2024 10:03:57 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/05/2024 10:00:35 PM
- TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024 • GlobeNewswire Inc. • 02/28/2024 09:02:00 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 09:31:59 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/09/2024 09:05:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/19/2023 10:00:08 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/08/2023 10:00:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2023 01:05:40 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 10:00:31 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/06/2023 09:00:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/18/2023 12:10:44 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/07/2023 08:11:15 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2023 09:01:24 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2023 08:12:31 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/07/2023 09:02:56 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 07/25/2023 09:19:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/11/2023 12:08:13 PM
ILUS Provides an Update on the Binding Term Sheet Signed with Actelis Networks (NASDAQ: ASNS) • ILUS • May 31, 2024 12:52 PM
Element79 Gold To Provide Summary and Update on Active Exploration Program, Community Relations at RMEC on June 4 • ELEM • May 30, 2024 1:18 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM